Evoke Pharma Pre-Paid Expenses 2012-2024 | EVOK

Evoke Pharma pre-paid expenses from 2012 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
Evoke Pharma Annual Pre-Paid Expenses
(Millions of US $)
2023 $1
2022 $1
2021 $1
2020 $1
2019 $1
2018 $0
2017 $0
2016 $0
2015 $1
2014 $1
2013 $0
2012 $
2011 $0
Evoke Pharma Quarterly Pre-Paid Expenses
(Millions of US $)
2024-06-30 $0
2024-03-31 $1
2023-12-31 $1
2023-09-30 $0
2023-06-30 $0
2023-03-31 $1
2022-12-31 $1
2022-09-30
2022-06-30 $0
2022-03-31 $1
2021-12-31 $1
2021-09-30
2021-06-30 $0
2021-03-31 $1
2020-12-31 $1
2020-09-30 $0
2020-06-30 $0
2020-03-31 $0
2019-12-31 $1
2019-09-30 $1
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $0
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $1
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $1
2015-12-31 $1
2015-09-30 $1
2015-06-30 $1
2015-03-31 $1
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $0
2013-12-31 $0
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.004B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Teligent (TLGT) United States $0.000B 0.00